Alphyn to Present Zabalafin Hydrogel Results at EADV 2024

Alphyn Biologics, Inc., a dermatology-focused clinical-stage company, has announced that data from its Phase 2a human clinical trial of Zabalafin Hydrogel (AB-101a) will be showcased at the European Academy of Dermatology and Venereology (EADV) Congress 2024 in Amsterdam from September 25-28. The company is developing Zabalafin Hydrogel as the first therapy specifically targeting the itch and bacterial causes of inflammation in atopic dermatitis (AD). Additionally, the treatment addresses infected AD skin and inflammation directly.

The Phase 2a trial was designed to evaluate critical treatment factors for AD such as itch alleviation, quality of life enhancement, and the overall safety and efficacy of Zabalafin Hydrogel. AD, a chronic skin condition, is the most prevalent type of eczema, recognized as a leading dermatological issue globally, according to the Global Atopic Dermatitis Atlas (GADA). Strong clinical outcomes for Zabalafin Hydrogel suggest its potential to become the preferred treatment for AD.

The clinical trial poster, titled "Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin," includes contributions from a team of medical professionals: Dr. Lynda Spelman, Dr. Stephen Shumack, Dr. Michael Benson, Dr. Bevin Bhoyrul, Dr. Jessie Lee, Dr. Ebrahim AK Abdulla, Neal Koller, and Gary Pekoe, PhD.

Zabalafin Hydrogel represents a novel botanical drug featuring multiple bioactive compounds that offer varied mechanisms of action, such as anti-pruritic, antibacterial, and anti-inflammatory effects. This topical treatment originates from Alphyn's proprietary Zabalafin Platform.

Alphyn Biologics is committed to developing unique Multi-Target Therapeutics® for severe and widespread skin conditions, leveraging its Zabalafin Platform. The company's flagship product, Zabalafin Hydrogel, has shown promise in Phase 2a trials and is aimed at directly addressing the core symptoms of AD, including itch and bacterial inflammation. The clinical evidence suggests Zabalafin Hydrogel has the potential to become a first-choice treatment for AD, suitable for long-term use without significant concerns.

The Zabalafin Platform features multiple bioactive compounds, enabling a range of mechanisms to support a comprehensive portfolio of dermatological treatments. These therapeutics could offer advantages in safety, side effects, patient tolerability, efficacy, and regulatory approval. Alphyn Biologics is headquartered in both Annapolis, Maryland, and Cincinnati, Ohio, and operates subsidiaries in Australia and Austria. Founded in 2020, the company has successfully raised approximately $16 million to date.